CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Active
Elrexfio elranatamab Relapsed or refractory multiple myeloma Active
Orgovyx relugolix Advanced prostate cancer Active
Tecvayli teclistamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Active
Keytruda pembrolizumab Biliary tract carcinoma Active
Beqvez fidanacogene elaparvovec Hemophilia B Reimburse with clinical criteria and/or conditions Active
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Active
TBC clindamycin plus benzoyl peroxide and adapalene acne vulgaris Active
Epidiolex cannabidiol Seizures associated with Tuberous Sclerosis Complex (TSC) Reimburse with clinical criteria and/or conditions Active
Qulipta atogepant Migraine, prevention Active
Last Updated : May 10, 2024